Stock AnalizCellebrite DI Ltd. CLBT
Computer Software: Prepackaged Software · data as of November 13, 2026
Cellebrite DI Ltd. (CLBT) is a technology company listed in the US with a market value of about $2.9B. In the twelve months to September 30, 2026 it had revenue of $537M and net income of $65M, a net margin of 12.0%.
Its overall Stock Analiz score is 2.8 out of 5 (average). The strongest part is future growth (5/5); the weakest is shareholder returns (0/5).
Key numbers: a P/E of 45.0, a price to free cash flow of 20.4, 5-year revenue growth of 20% a year, a 5-year average ROIC of 20%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 31% below the current price.
Score: 2.8 / 5
Checks passed
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- 5-year EPS growth above 10% a year
- Profitable 5 years in a row
- Pays a dividend
- Share count down over 3 years (buybacks)
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $537M | $476M | $401M | $325M | $271M | $246M | $195M | $172M |
| Net income | $65M | $78M | -$283M | -$81M | $121M | $71M | $6M | -$2M |
| Free cash flow | $142M | $160M | $124M | $97M | $14M | $31M | $60M | $10M |
| EPS (diluted) | $0.26 | $0.31 | $-1.13 | $-0.32 | $0.48 | $0.28 | $0.02 | $-0.01 |
| Net margin | 12.0% | 16.5% | -70.5% | -24.9% | 44.6% | 29.0% | 3.0% | -1.1% |
| ROIC | — | 11.3% | 13.0% | 54.3% | 0.9% | — | 7.3% | -2.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $15.43, 34% above the current price; targets range from $14.00 to $20.00; the consensus rating is “Strong buy”; expected EPS is $0.58 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Cellebrite DI’s P/E ratio?
About 45.0, based on the last twelve months of diluted earnings per share (forward P/E about 17.7).
Is Cellebrite DI stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 31% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Cellebrite DI pay a dividend?
Not currently.
Is Cellebrite DI a good stock to buy?
We do not give buy or sell advice. Cellebrite DI scores 2.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.